This Article Full Text (PDF) Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bolster, A A Articles by Barrett, A Search for Related Content PubMed PubMed Citation Articles by Bolster, A A Articles by Barrett, A

Dosimetric considerations in ¹³¹I-MIBG therapy for neuroblastoma in children

¹ Department of Clinical Physics and Bio-Engineering, Western Infirmary, Glasgow, UK ² Department of Radiation Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow, UK

Dosimetric calculations have been made for organ doses in patients receiving ¹³¹I-MIBG therapy as treatment for neuroblastoma. As well as whole body and liver dose, consideration has been given to dosimetry of organs (lung, urinary bladder) whose tolerance may become treatment limiting when ¹³¹I-MIBG is given as part of combined modality therapy. Data from both adults and children receiving radiolabelled MIBG for diagnostic or therapeutic purposes have been compared in constructing dosimetry models for children. A recently published urodynamic model has been used in the estimation of radiation dose to the bladder. The results show that liver and lung may receive doses greater than the average total body dose (0.58 mGy MBq^–1 and 0.35 mGy MBq^–1, respectively, as compared with 0.25 mGy MBq^–1 to the whole body). The organ dose estimates do not differ greatly from previous analyses except in the case of the bladder for which the new modelling studies have resulted in lower dose estimates (0.76 mGy MBq^–1 administered, for dose to bladder surface from bladder contents) than in some published series. This may result from differing assumptions regarding parameters such as bladder content and urine flow rate, an enhanced fluid intake being assumed in the present bladder dose estimates. Average doses to the bladder wall from the contents were estimated to be 7.4–11.3% of the surface doses. The urodynamic modelling analysis shows that the bladder could receive a much greater dose (by an order of magnitude) in patients who were inadequately hydrated or had impaired renal function.

^* Current address: Meyerstein Institute of Oncology, The Middlesex Hospital, London WIN 8AA, UK.

Received for publication September 19, 1994. Revision received November 21, 1994. Accepted for publication December 2, 1994.

This article has been cited by other articles:

				K. K. Matthay, C. Panina, J. Huberty, D. Price, D. V. Glidden, H. R. Tang, R. A. Hawkins, J. Veatch, and B. Hasegawa Correlation of Tumor and Whole-Body Dosimetry with Tumor Response and Toxicity in Refractory Neuroblastoma Treated with 131I-MIBG J. Nucl. Med., November 1, 2001; 42(11): 1713 - 1721. [Abstract] [Full Text] [PDF]

				P. A. Vasey, S. B. Kaye, R. Morrison, C. Twelves, P. Wilson, R. Duncan, A. H. Thomson, L. S. Murray, T. E. Hilditch, T. Murray, et al. Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents--Drug-Polymer Conjugates Clin. Cancer Res., January 1, 1999; 5(1): 83 - 94. [Abstract] [Full Text] [PDF]